BioLab Holdings Provides Clinical Trial Updates Across CAMP Platform and Emerging Technologies
BioLab Holdings, Inc. has announced significant progress in its clinical trials evaluating wound care innovations and imaging technologies. The trials focus on BioLab’s Cellular, Acellular and Matrix-like Products (CAMPs), including new studies for Chronic Wounds such as Diabetic Foot Ulcers and Venous Leg Ulcers. Ongoing and upcoming studies aim to provide robust clinical evidence for the efficacy and safety of these innovative products.
Company advances multiple trials evaluating wound care innovations and imaging technologies PHOENIX, May 26, 2026 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical technology company focused on advancing tissue restoration through innovation, strategic partnerships, and…
